… Results of this study clearly show that the benefit of combining erlotinib and B-DIM will be
limited to cells that have EGFR pathway activation probably driven by NF-κB activation. …

… Patients in the treatment group received erlotinib according to BCCA protocols: erlotinib 150
… at which time erlotinib is discontinued [5]. The most common adverse effect of erlotinib is a …

… patients receiving erlotinib 150 mg/day than in those receiving placebo. Erlotinib is generally
… data suggests that second- or third-line erlotinib 150mg/day is a cost-saving option relative …

… In conclusion, single-agent erlotinib has minimal activity in the settings studied and additional
research should probably focus on multi-agent strategies, multi-targeting agents that may …

… Analyses of data from two large pivotal trials associated erlotinib treatment with significant
survival benefit in both SC and AD histology subgroups, supporting its efficacy in pts with SC …

… erlotinib 150 mg orally on days 2–15 every 3 weeks for four cycles followed by erlotinib 150
mg orally until PD occurred (CT + erlotinib). … (CT + erlotinib and erlotinib alone, respectively). …

… study was to compare the incremental cost-effectiveness ratios of strategies for second-line
erlotinib … (nonsmoking females with adenocarcinoma received erlotinib; all other patients …

… 隨機對照試 驗中,其中一個使用 erlotinib( OPTIMAL),另三個使用 … erlotinib 與gefitinib的無惡化
生存期的危險系數,發現erlotinib在… 把erlotinib與 gefitinib比較,成本效益評估模型顯示erlotinib的無…

… ), erlotinib (20 μM), and dasatinib (0.2 μM) [20]. In this study, the activity of axitinib, erlotinib,
and … Exposure of CRC cells to 2- and 3-drug combinations of axitinib, erlotinib, and dasatinib …

… PFS benefit from erlotinib than from chemotherapy, making erlotinib the … In conclusion, our
study demonstrates that erlotinib … Our study provides further support for the use of erlotinib in …